RTP biopharma lands $150M in new funding for kidney disease research
Pathalys Pharma, the Research Triangle Park-based biopharmaceutical company developing therapies for end-stage kidney disease, has secured $150 million in new financing to support phase 3 clinical trials for its leading drug candidate.
Read More
